albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Cytosine is a nucleotide that is present in both DNA and RNA. However, uracil is only found in RNA. Therefore, after UTP is synthesized, it must be converted into a deoxy form to be incorporated into DNA. This conversion involves the enzyme ribonucleoside triphosphate reductase. This reaction that removes the 2'-OH of the ribose sugar to generate deoxyribose is not affected by the bases attached to the sugar. This non-specificity allows ribonucleoside triphosphate reductase to convert all nucleotide triphosphates to deoxyribonucleotide by a similar mechanism. In contrast to uracil, thymine bases are found mostly in DNA, not RNA. Cells do not normally contain thymine bases that are linked to ribose sugars in RNA, thus indicating that cells only synthesize deoxyribose-linked thymine. The enzyme thymidylate synthetase is responsible for synthesizing thymine residues from dUMP to dTMP. This reaction transfers a methyl group onto the uracil base of dUMP to generate dTMP. The thymidylate synthase reaction, dUMP + 5,10-methylenetetrahydrofolate ⇔ dTMP + dihydrofolate, is shown to the right.
In March 2010, the Center for Public Integrity released a report that Bush's administration had made more than 900 false pretenses in a two-year period about the alleged threat of Iraq against the United States, as his rationale to engage in war in Iraq.
== J == Sophie E. Jackson (active from 1991). Biochemist at the University of Cambridge known for work on protein folding. Alec Jeffreys FRS (b. 1950). British biochemist and geneticist at Leicester University, known for inventing genetic fingerprinting. William Jencks FRS (foreign member) (1927–2007). American biochemist at Brandeis University, known for applying chemical mechanisms to enzyme-catalysed reactions and for his masterly book Catalysis in Chemistry and Enzymology. Member Natl. Acad. Sci. USA. Thomas H. Jukes (1906–1999). British-American biologist at UC Berkeley known for work in nutrition and molecular evolution. He was very active in denouncing pseudoscience. John Michael Jumper (b. 1985). American chemist and computer scientist at DeepMind Technologies. Nobel Prize in chemistry, 2024.
A moment was a medieval unit of time. The movement of a shadow on a sundial covered 40 moments in a solar hour. An hour in this case meant one twelfth of the period between sunrise and sunset. The length of a solar hour depended on the length of the day, which in turn varied with the season, so the length of a moment in modern seconds was not fixed, but on average, a moment corresponded to 90 seconds.
=== U.S. federal government actions === In 2002, a panel of toxicologists, including several from EPA, proposed a level of 150 ppb for drinking water in the PFOA contaminated area around DuPont's Washington Works plant. This initially proposed level was much higher than any known environmental concentration and was over 2,000 times the level EPA eventually settled on for the drinking water health advisory. In July 2004, EPA filed a suit against DuPont alleging "widespread contamination" of PFOA near the Parkersburg, West Virginia plant "at levels exceeding the company's community exposure guidelines"; the suit also alleged that "DuPont had—over a 20 year period—repeatedly failed to submit information on adverse effects (in particular, information on liver enzyme alterations and birth defects in offspring of female Parkersburg workers)." In October 2005, a USFDA study was published revealing PFOA and PFOA precursor chemicals in food contact and PTFE products. On January 25, 2006, EPA announced a voluntary program with several chemical companies to reduce PFOA and PFOA precursor emissions by the year 2015. On February 15, 2005, EPA's Science Advisory Board (SAB) voted to recommended that PFOA should be considered a "likely human carcinogen". On May 26, 2006, EPA's SAB addressed a letter to Administrator Stephen L. Johnson. Three-quarters of advisers thought the stronger "likely to be carcinogenic" descriptor was warranted, in opposition to EPA's own PFOA hazard descriptor of "suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential".
Sources: en.wikipedia.org
Moore began announcing nominations for his 26-member cabinet on November 14, 2022. He finished announcing his cabinet nominees on April 12, 2023, with the nomination of Sanjay Rai as Secretary for the Maryland Higher Education Commission. According to The Baltimore Banner, Moore assembled his cabinet at a slower pace than previous Maryland governors. Three of Moore's Cabinet nominees, Secretary of Emergency Management Russell Strickland, Maryland State Police superintendent Roland Butler, and Secretary of Public Safety and Correctional Services Carolyn Scruggs, are holdovers from the Hogan administration. As his chief of staff, Moore chose Fagan Harris, who co-founded the Baltimore Corps organization with Moore a decade ago. Moore also named three members of the Maryland General Assembly to his administration: state senator Paul G. Pinsky as director of the Maryland Energy Administration; state senator Susan C. Lee as Secretary of State; and House of Delegates Majority Leader Eric Luedtke as chief legislative officer. Other notable Cabinet nominations included Salisbury mayor Jacob R. Day as Secretary of Housing and Community Development, former New York City Department of Correction commissioner Vincent Schiraldi as Secretary of Juvenile Services, Anthony Woods as Secretary of Veterans Affairs, and former WMATA general manager Paul Wiedefeld as Secretary of Transportation.
=== International and Enterprise divisions === UPMC's International and Commercial Services Division (ICSD) actively manages UPMC's for-profit companies that seek to commercialize its expertise in health care, advanced technologies, and management skills to global markets. Its stated goal is "to advance UPMC's mission of positively transforming the way health care is provided in the U.S. and abroad, while revitalizing the economy of western Pennsylvania." UPMC International provides health care consulting and management services around the world in areas in various areas including clinical program development, facility and construction planning, clinical investigation, clinical and administrative staff training, and health information technology, and quality, safety, and Innovation. UPMC Enterprises is an innovation and commercialization arm of UPMC which has invested over $700 million in about 80 different ventures in the past twenty years. It seeks to create products and business arising from translational science and technology solutions by collaborating with entrepreneurs. In the past, it has also forged collaborations with companies such as dbMotion) and strategic and commercial product development partnerships with companies such as IBM and Alcatel-Lucent. UPMC Enterprises portfolio includes such companies as ALung, and Prodiogo Solutions.
=== Pharmacodynamics === Methocinnamox is an opioid receptor antagonist, it works at the μ-opioid receptor. By acting as an antagonist, it binds to the receptor but does not activate it, thus blocking the action of agonists such as heroin and fentanyl. It is a pseudo-irreversible non-competitive antagonist of the μ-opioid receptor and a competitive antagonist of the κ- and δ-opioid receptors. Methocinnamox has affinity values for the opioid receptors of 0.6 nM for the μ-opioid receptor, 2.2 nM for the δ-opioid receptor, and 4.9 nM for the κ-opioid receptor. Hence, it has about 3.7-fold preferential affinity for the μ-opioid receptor over the δ-opioid receptor and about 8.2-fold higher affinity for the μ-opioid receptor over the κ-opioid receptor. The antagonism of the μ-opioid receptor by methocinnamox is not irreversible as the drug does not form a covalent bond with the receptor. This is in contrast to prototypical μ-opioid receptor alkylating agents like β-funaltrexamine and β-chlornaltrexamine. However, in spite of its lack of covalent binding to the μ-opioid receptor, methocinnamox appears to not dissociate from the μ-opioid receptor or dissociates from it extremely slowly. Hence, methocinnamox has been described as a pseudo-irreversible antagonist of the μ-opioid receptor or as a "functionally irreversible" antagonist. The mechanism underlying the pseudo-irreversible antagonism of methocinnamox hasn't been fully elucidated.
== History == Nutmeg has been used as a spice by Indian and Arab civilizations as early as 700 BC. It was subsequently introduced into Europe by merchants and traders by 1195 AD. Reports of the intoxicating effects of nutmeg date back to the Middle Ages by Hildegard von Bingen or to ancient times. The first clear mention of nutmeg's psychoactive effects was in 1576, describing a woman becoming "deliriously inebriated". Nutmeg did not become a significant recreational drug in modern times until after World War II. The effects of the aromatic volatile fraction of nutmeg thought to be responsible for its psychoactive effects were first studied and described in humans in 1961. Alexander Shulgin suggested biotransformation into amphetamines in 1963. However, experimental findings contradicted this theory by the 1970s and thereafter. Preclinical research suggesting an indirect cannabinoid or cannabimimetic mechanism of action was published over the time period of 2009 to 2019.
In December 2022, the company announced initial phase 1 clinical trial results for its flu vaccine patch. In 2023, Vaxess and AstraZeneca announced the development of a skin patch for mRNA vaccines focused on pandemic flu. In May 2024, Vaxess announced $12 million in funding and named Rachel Sha as CEO of the company. In May 2025, Vaxess announced $9 million in funding to advance its work in GLP-1, and . In June, the company presented new clinical data on the capability of its drug delivery patch to deliver semaglutide.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.